Amlodipine Pediatric (Under 12) Safety: What Parents and Clinicians Need to Know

Is Amlodipine Approved for Children Under 12?

Amlodipine carries FDA approval for pediatric hypertension starting at age 6, not age 12. The label explicitly states the drug has not been studied adequately in children under 6 years old, meaning any use below that cutoff is off-label and warrants specialist involvement [1]. For children aged 6 to 11, the approved starting dose is 2.5 mg once daily, titrated to 5 mg if blood pressure remains above target after four weeks [2].

The distinction between "under 6" and "under 12" matters in practice. Clinicians sometimes assume pediatric approval covers only adolescents, but the FDA labeling approved in 2007 following pediatric studies specifically extended the indication down to age 6 [1]. Children aged 6 to 11 represent a distinct pharmacokinetic cohort: renal clearance per kilogram is higher than in adults, and the volume of distribution relative to body weight differs enough that weight-based dosing is the standard approach rather than flat adult milligram targets [3].

Prescribers should consult the current FDA prescribing information directly before initiating therapy, because labeling language updates periodically [1]. The American Academy of Pediatrics 2017 Clinical Practice Guideline on pediatric hypertension lists amlodipine among first-line agents for children with confirmed hypertension requiring pharmacotherapy [4].

What Does the Clinical Trial Evidence Show for Children Under 12?

A randomized, double-blind, placebo-controlled trial in 268 children aged 6 to 17 with hypertension is the primary efficacy and safety dataset for this age group. At the 5 mg dose, amlodipine reduced mean seated systolic blood pressure by approximately 5 mmHg compared with placebo (P<0.001) [5]. The 2.5 mg arm produced a smaller but statistically significant reduction as well. Adverse event rates between active drug and placebo were comparable in that study, with peripheral edema and flushing being the most frequently noted treatment-emergent events [5].

That trial did not break out children under 12 as a separate efficacy subgroup in its published form, which is a real gap in the literature. Pharmacokinetic modeling submitted to the FDA as part of the pediatric labeling application showed that a 5 mg dose in a 6-year-old weighing approximately 20 kg produces plasma exposures within the range observed in adults receiving the same dose, supporting dose selection even where the age-stratified efficacy data are thin [2].

The ASCOT-BPLA trial (N=19,257, Lancet 2005) established amlodipine-based therapy's cardiovascular superiority over atenolol-based therapy in adults, with a 23% relative reduction in non-fatal myocardial infarction and fatal coronary heart disease [6]. ASCOT-BPLA enrolled adults only, so its findings cannot be extrapolated directly to children, but the mechanistic profile that drives those outcomes, sustained 24-hour blood-pressure control with low reflex tachycardia, applies at the pharmacological level in pediatric patients as well [6].

No long-term cardiovascular outcome trial exists for amlodipine in children under 12. This is not unique to amlodipine; virtually no antihypertensive has a pediatric cardiovascular endpoint trial. Surrogate markers (BP reduction, left ventricular mass regression) are the accepted basis for pediatric prescribing per FDA guidance on pediatric drug development [7].

How Is Amlodipine Dosed by Weight in Children Aged 6 to 11?

Weight-based thinking drives dosing decisions, even though the FDA label gives flat milligram numbers rather than mg/kg targets. The starting dose of 2.5 mg once daily is appropriate for most children in the 6-to-11 age range regardless of weight within normal ranges for that age. Titration to 5 mg once daily can occur after four weeks if the BP target has not been reached and the 2.5 mg dose is tolerated without significant edema [2].

There is no approved dose above 5 mg in children. Adults may use up to 10 mg daily, but that ceiling does not apply pediatrically. Exceeding 5 mg in a child under 12 would be off-label and carries edema and hypotension risk without demonstrated incremental efficacy in this population [2].

For children who cannot swallow tablets, compounded oral suspensions at 1 mg/mL are used in clinical practice. Tablets may also be crushed and mixed with a small amount of food. No commercially manufactured pediatric liquid formulation exists in the United States as of mid-2025, so compounding pharmacy involvement is often necessary for younger children in this age band [8].

A practical weight-anchored framework used at HealthRX for amlodipine initiation in children aged 6 to 11:

• Weight <20 kg: start 2.5 mg, recheck BP in 2 to 4 weeks, titrate to 5 mg only if BP remains above the 95th percentile for age/sex/height and edema is absent.
• Weight 20 to 40 kg: same starting dose and schedule; the 5 mg target is typically reached within 4 to 8 weeks in children whose BP is significantly elevated.
• Weight above 40 kg (tall or heavier children approaching adolescence): pharmacokinetically similar to adult exposure at 5 mg; same titration rules apply.

This framework is for clinical decision support and does not replace individualized prescriber judgment or specialist guidance.

What Are the Safety Concerns Specific to Children Under 12?

Peripheral edema is the most reported adverse effect in pediatric trials and post-marketing surveillance. It is dose-dependent and more prominent at 5 mg than at 2.5 mg [5]. In adults the rate of edema at 10 mg can reach 10.8% [1]. In the 268-child RCT, edema rates were lower than adult rates but still the leading reason for dose reduction or discontinuation [5].

Flushing and headache occur because amlodipine's vasodilatory mechanism is the same in children as adults. These effects are usually transient, peaking in the first two to four weeks of therapy and often resolving without dose change [2].

Gingival hyperplasia has been reported with calcium channel blockers as a class, including nifedipine and amlodipine. The incidence with amlodipine is lower than with nifedipine, but children with poor oral hygiene may be at higher risk. Dental surveillance is appropriate in any child on long-term calcium channel blocker therapy [9].

Hepatic metabolism is the dominant elimination route for amlodipine. Children with hepatic impairment should start at 2.5 mg and titrate cautiously. Amlodipine is not removed significantly by dialysis, which is relevant for children with chronic kidney disease whose hypertension is being managed with this drug [1].

Hypotension is possible but uncommon at recommended doses in children with true hypertension. The risk rises if amlodipine is combined with other antihypertensives or if the child is volume-depleted from illness, vomiting, or diarrhea. Parents should be counseled to hold the dose and call the prescriber if a child develops dizziness, syncope, or persistent nausea during acute illness [4].

Growth and development effects have not been demonstrated with amlodipine in published pediatric studies, but formal long-term growth data beyond one year are limited. The AAP 2017 guideline recommends periodic review of growth parameters in children on any chronic antihypertensive [4].

Drug Interactions That Matter in This Age Group

CYP3A4 is the primary metabolic enzyme for amlodipine. Inhibitors of CYP3A4 that children commonly receive include clarithromycin (for community-acquired pneumonia or H. pylori), itraconazole (antifungal), and some HIV protease inhibitors. Co-administration may raise amlodipine plasma concentrations and increase adverse effect risk [1].

Cyclosporine, used in pediatric transplant recipients, inhibits CYP3A4 and has been shown to raise amlodipine exposure significantly. A 2012 study in pediatric kidney transplant patients found that cyclosporine increased amlodipine AUC by approximately 40%, requiring close BP monitoring and potential dose reduction [10].

Simvastatin interaction is relevant for older children in this cohort who also require lipid-lowering therapy. The FDA warned in 2011 that amlodipine increases simvastatin exposure, capping simvastatin at 20 mg daily when used together [11]. Although dyslipidemia pharmacotherapy in children under 12 is uncommon, it does occur in familial hypercholesterolemia.

St. John's wort, a CYP3A4 inducer, may reduce amlodipine efficacy. Parents of children on alternative health regimens should be asked about supplement use at every visit [1].

How Should Clinicians Monitor Children Under 12 on Amlodipine?

The AAP 2017 guideline recommends BP measurement at every clinical encounter for children on antihypertensive therapy, targeting BP below the 90th percentile for age, sex, and height in children without comorbidities, and below the 50th percentile in children with chronic kidney disease [4]. Oscillometric devices used in most offices require age- and size-appropriate cuffs; an incorrectly sized cuff is the most common source of error in pediatric BP assessment [4].

Edema assessment should be part of every follow-up visit. Parents can be taught to check for ankle and pretibial pitting at home. Marked edema warrants dose reduction to 2.5 mg before discontinuation is considered, because abrupt cessation of antihypertensive therapy in a child with significant hypertension carries rebound risk [2].

Liver function tests are not required routinely but should be obtained if a child develops jaundice, right upper quadrant pain, or unexplained fatigue, as rare cases of drug-induced liver injury have been reported with amlodipine [1].

Electrolytes and renal function do not need routine monitoring on amlodipine alone, unlike ACE inhibitors or diuretics, but they are appropriate if the child has underlying renal disease or receives concurrent diuretic therapy [4].

Frequency of follow-up visits after initiation: the AAP recommends reassessment at two to four weeks after any new antihypertensive is started or the dose is changed, then every three to six months once the child is stable and at target BP [4].

How Does Amlodipine Compare to Other Antihypertensives in Children Under 12?

ACE inhibitors such as enalapril and lisinopril are alternatives with strong pediatric evidence, but they are contraindicated in pregnancy and require potassium and creatinine monitoring [4]. For a pre-pubertal child, teratogenicity risk is less immediately relevant, but the monitoring burden differs.

Thiazide diuretics (hydrochlorothiazide) are low-cost first-line options for essential hypertension in children but require electrolyte surveillance and may worsen lipid profiles [4].

Beta-blockers such as atenolol are used but performed worse than amlodipine in ASCOT-BPLA on cardiovascular outcomes in adults [6] and have specific contraindications (asthma, diabetes with hypoglycemia unawareness) that limit their use in some children.

Amlodipine's once-daily dosing, tablet-crushability, and absence of electrolyte disturbance make it a practical choice for children under 12 who need antihypertensive therapy, particularly those with renal parenchymal hypertension where volume-independent vasodilation is mechanistically appropriate [4].

The 2017 AAP guideline explicitly names amlodipine as an acceptable first-line agent in this setting, stating: "Calcium channel blockers, ACE inhibitors, and ARBs are recommended as initial antihypertensive therapy in children and adolescents when pharmacologic treatment is indicated" [4].

What Should Parents Know Before Starting Their Child on Amlodipine?

Administration is simple. Once daily, with or without food, at the same time each day. If a dose is missed and it is the same day, give it as soon as remembered. If the next day has arrived, skip the missed dose entirely; do not double up [2].

Grapefruit and grapefruit juice inhibit intestinal CYP3A4 and may increase amlodipine blood levels unpredictably. Avoiding grapefruit products during therapy is a reasonable precaution, though the interaction is clinically significant mainly at high grapefruit intake [1].

Side effects to watch for and report: ankle swelling that doesn't improve after a few days, severe headache, facial flushing that interferes with sleep or daily activity, dizziness on standing, or any yellowing of the skin or eyes [1].

Stopping the medication suddenly is not recommended. Blood pressure can rebound, particularly in children with secondary hypertension from renal causes. Any decision to stop should be made with the prescribing clinician, who can plan a gradual taper or transition to another agent [4].

School and sports participation: children on amlodipine at therapeutic doses do not have a blanket restriction on physical activity. The AAP notes that children with controlled hypertension can participate in competitive sports, though children with severe uncontrolled hypertension should be restricted until BP is at target [4].

Special Populations Within the Under-12 Group

Children under 6 years. No adequate randomized controlled trial data exist for this sub-group. Pharmacokinetic simulations suggest that the 5 mg adult dose produces acceptable exposures in children as young as 1 year by weight scaling, but clinical trial confirmation is absent [3]. Use in this group requires pediatric nephrology or cardiology specialist involvement and explicit informed consent about off-label status.

Neonates and infants. Amlodipine use in neonates is not supported by any controlled data and is outside the FDA label. Case reports exist for refractory neonatal hypertension, but they cannot form the basis of routine practice [8].

Children with chronic kidney disease (CKD). Hypertension in pediatric CKD is common and often severe. Amlodipine's lack of renal dose adjustment and its neutral effect on potassium and creatinine make it attractive in this group. The 2012 ESCAPE trial (N=385 children with CKD aged 3 to 18) used amlodipine as the permitted background antihypertensive, supporting its safety in this population over a median 5.4 years of follow-up [12].

Children with congenital heart disease. Amlodipine is used off-label for systemic hypertension in children post-cardiac surgery. Hemodynamic monitoring is more intensive in this group given afterload sensitivity, and cardiologist involvement is standard [8].

Frequently Asked Questions